Prospective Cohort Study Investigating Changes in Body Image, Quality of Life, and Self-Esteem Following Minimally Invasive Cosmetic Procedures

BACKGROUND Minimally invasive cosmetic injectable procedures are increasingly common. However, a few studies have investigated changes in psychosocial functioning following these treatments. OBJECTIVE To assess changes in body image, quality of life, and self-esteem following cosmetic injectable treatment with soft tissue fillers and neuromodulators. METHODS Open, prospective study of 75 patients undergoing cosmetic injectable procedures for facial aging to evaluate changes in psychosocial functioning within 6 weeks of treatment. Outcome measures included the Derriford appearance scale (DAS-24), body image quality of life inventory (BIQLI), and the Rosenberg self-esteem scale. RESULTS Body image dissatisfaction, as assessed by the DAS-24, improved significantly 6 weeks after the treatment. Body image quality of life, as assessed by the BIQLI, improved, but the change did not reach statistical significance. Self-esteem was unchanged after the treatment. CONCLUSION Minimally invasive cosmetic injectable procedures were associated with reductions in body image dissatisfaction. Future research, using recently developed cosmetic surgery-specific instruments, may provide further insight into the psychosocial benefits of minimally invasive procedures. Address correspondence and reprint requests to: Joseph F. Sobanko, MD, Mohs & Reconstructive Surgery, Division of Dermatologic Surgery, Dermatology, University of Pennsylvania Health System, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, or e-mail: joseph.sobanko@uphs.upenn.edu J.F. Sobanko is supported by a Dermatology Foundation Clinical Career Development Award in Dermatologic Surgery and a University of Pennsylvania Center for Human Appearance Grant. J.M. Gelfand is supported by NIH/NIAMS grant K24AR064310. In the previous 12 months, J.M. Gelfand served as a consultant for Coherus (DSMB), Dermira, Janssen Biologics, Merck (DSMB), Novartis, Corp., Regeneron, Sanofi, and Pfizer, Inc., receiving honoraria and receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis, Corp., Regeneron, Sanofi, Celgene, and Pfizer, Inc., and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly and Abbvie. J.M. Gelfand is a copatent holder of resiquimod for the treatment of cutaneous T-cell lymphoma. D.B. Sarwer has consulting relationships with Allergan, BARONova, Ethicon, and Novo Nordisk. He also serves on the Board of Directors for the American Board of Plastic Surgery and the American Society for Aesthetic Plastic Surgery Research Foundation. I. Percedc is a consultant for Galderma. The remaining authors have indicated no significant interest with commercial supporters. This study was approved by the institutional review board of the University of Pennsylvania. © 2018 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2JL7cfu